Peptonic Medical AB (PMED) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.38

Return on Equity

-126.16%

Price to Book

0.00

Revenue and Profits:

Net Sales:

5 Million

(Quarterly Results - Jun 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

71.43%

6 Months

-7.69%

1 Year

-29.41%

2 Years

-95.06%

3 Years

-98.21%

4 Years

-99.14%

5 Years

-99.72%

Peptonic Medical AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.89%

EBIT Growth (5y)

-25.15%

EBIT to Interest (avg)

-42.07

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.12

Sales to Capital Employed (avg)

0.39

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

-0.12

EV to EBITDA

-0.13

EV to Capital Employed

0.12

EV to Sales

0.36

PEG Ratio

Dividend Yield

ROCE (Latest)

-98.31%

ROE (Latest)

-96.07%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 28.95% vs -13.64% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 53.33% vs 71.91% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.90",
          "val2": "3.80",
          "chgp": "28.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.30",
          "val2": "-6.00",
          "chgp": "45.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.50",
          "val2": "-7.50",
          "chgp": "53.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-960.90%",
          "val2": "-1,984.80%",
          "chgp": "102.39%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.49% vs -14.91% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.85% vs -15.45% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "26.90",
          "val2": "37.10",
          "chgp": "-27.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-59.60",
          "val2": "-36.00",
          "chgp": "-65.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "2.30",
          "chgp": "-39.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-60.00",
          "val2": "-42.60",
          "chgp": "-40.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,465.00%",
          "val2": "-1,138.30%",
          "chgp": "-132.67%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

4.90

3.80

28.95%

Operating Profit (PBDIT) excl Other Income

-3.30

-6.00

45.00%

Interest

0.10

Exceptional Items

0.00

Consolidate Net Profit

-3.50

-7.50

53.33%

Operating Profit Margin (Excl OI)

-960.90%

-1,984.80%

102.39%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 28.95% vs -13.64% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 53.33% vs 71.91% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

26.90

37.10

-27.49%

Operating Profit (PBDIT) excl Other Income

-59.60

-36.00

-65.56%

Interest

1.40

2.30

-39.13%

Exceptional Items

0.00

Consolidate Net Profit

-60.00

-42.60

-40.85%

Operating Profit Margin (Excl OI)

-2,465.00%

-1,138.30%

-132.67%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -27.49% vs -14.91% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -40.85% vs -15.45% in Dec 2023

All Annual Results

Company CV

About Peptonic Medical AB

Peptonic Medical AB

Pharmaceuticals & Biotechnology

Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company's main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.

Company Coordinates

Company Details

Gustavslundsvagen 143 , BROMMA None : 167 51

Tel: 46 8 53020110

http://peptonicmedical.se

Registrar Details